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Introduction
Preterm premature rupture of membranes (PPROM) is
a complication in approximately one-third of all preterm
deliveries, and involves a high risk of fetal and mater-
nal morbidity [1]. Among twins with PPROM, approx-
imately 6% were stillbirths, 15% were neonatal deaths
and 14% were reported as infant mortality, in the
United States [2]. Those twins with extremely preterm
premature rupture of membranes (EPPROM) prior to
20 weeks exhibited worse results. Assisted reproduction
technology (ART) for infertile couples is strongly asso-
ciated with twinning and twins remain a high-risk
group compared with singletons [3]. Among people
having difficulty conceiving, prolongation of twin preg-
nancies was more frequently claimed. We have previ-
ously obtained some twins with EPPROM of the upper
[4] or lower sac [5].
The most common tocolytic agents used in preterm
labor are ritodrine (Yutopar) and magnesium sulfate
(MgSO4). However, betamimetics like ritodrine are sig-
nificantly associated with palpitations, nausea, tremor,
chorioamnionitis, hyperglycemia and hypokalemia [6],
therefore treatment needs to be discontinued. A recent
double-blind trial of MgSO4 used between 24 and 31
weeks failed to reduce the risk of cerebral palsy or death
due to preterm delivery [7]. In addition, compromised
respiration after MgSO4 therapy for preterm labor was
also a concern [8]. Recently, atosiban (Tractocile) was
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SUMMARY
Objective: Pregnancies with extremely preterm premature rupture of membranes (EPPROM), especially before
20 weeks of gestation, are usually considered to be a termination of pregnancy. By improvement of obstetric
and neonatal care, we can prolong the pregnancy across the threshold of survival by aggressive tocolysis.
Case Report: Using intrauterine insemination, a 32-year-old woman became pregnant with twins (first pregnancy).
Threatened abortion occured since 9 weeks of gestation and EPPROM of the upper twin was noted at 18 weeks.
Massive vaginal bleeding and vigorous uterine contractions occurred at 22 weeks. Poor control of preterm labor
occurred using ritodrine and MgSO4. Atosiban was applied to calm uterine activities. After discontinuation of
atosiban at 30 weeks, the uterine contractions became severe again and an emergency cesarean section was
performed to deliver two live, premature babies weighing 1,518 g and 830 g, respectively. Twin A was healthy,
weighing 2,030 g at 35 days after birth and subsequently discharged. The smaller twin B was dependent on con-
tinuous positive airway pressure and died of pulmonary infection 120 days after birth.
Conclusion: Comparing to other tocolytic agents, Atosiban has few side effects and assisted in prolonging a
pregnancy involving twins that experienced EPPROM. [Taiwan J Obstet Gynecol 2010;49(4):495–499]
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introduced for delaying preterm delivery before the
threshold of viability [9]. More recently, a randomized
study in Korea [10] demonstrated that atosiban, a
highly uterospecific tocolytic agent, was superior to
ritodrine in both safety and efficacy.
Case Report
A 32-year-old woman achieved her first pregnancy
(twins) by intrauterine insemination. Prior to this, she
suffered from 2 years of infertility due to ovarian dys-
function, and an irregular menstrual cycle with mild
hirsutism compatible with polycystic ovary syndrome.
She also received a laparoscopic left oophorocystec-
tomy for a chocolate cyst (6 × 5 × 5 cm). At 9+3 gesta-
tional weeks, she was admitted due to vaginal bleeding
and pelvic cramps. Pelvic ultrasound revealed a sub-
chorionic hematoma measuring 3.9 × 3.0 × 2.5 cm
beneath twin B. Complete bed rest was prescribed and
oral progesterone (Utrogestan) dosage was increased
from 300 mg to 600 mg per day. She was discharged 
5 days later, and the vaginal bleeding had stopped. The
hematoma had grown to 7.1 × 4.8 × 6.1 cm at 12 weeks.
The second trimester maternal serum screening returned
the result of a high risk of Down’s syndrome (1/84),
and the patient was advised to undergo amniocentesis.
At 18 weeks and 1 day, amniocentesis was per-
formed. The biparietal diameter (BPD) was measured
as 4.0 cm of twin A (right lower, female), and 3.8 cm of
twin B (left upper, male). The evening after amniocen-
tesis, the patient felt apparent fluid leakage from the
vagina. A follow up ultrasound revealed nearly no
amniotic fluid for twin B, so iatrogenic EPPROM was
documented. The results of chromosome and spinal
muscular atrophy screening were normal. Fetal screen-
ing ultrasound performed at 19 weeks demonstrated
anhydramnios of twin B. Repeated sonography at 21,
22, 23 weeks showed identical results. At 22 weeks
and 5 days, she visited our emergency department due
to sudden onset of vaginal bleeding (hemoglo-
bin = 10.0 g/dL). There were some blood clots and
mucus from the cervix, with the cervix slightly effaced
but not dilated. After discussion with the patient and her
family about the risk and prognosis, they chose to
allow the pregnancy to continue. Due to prolonged
EPPROM for 2 more weeks, intravenous antibiotics
(Cefa) were given despite low C-reactive protein (CRP)
levels (0.8 mg/dL). When ritodrine was infused at a
dosage of 8 mg per hour, the patient complained of
severe palpitation and nausea but the uterine contrac-
tions were still active (3–5-minute intervals). Atosiban
was added to control the preterm labor, and on the
next day, MgSO4 was added to attenuate the uterine
contractions. The tocolytic agents were kept near the
highest threshold: ritodrine 20.8 mg/hr, MgSO4 1.6 g/hr,
atosiban 9 mg/hr. The CRP levels peaked at 4.68 mg/dL
at 3 days post-admission and fluctuated thereafter.
Cervical cultures were performed once or twice per week,
and antibiotics changed according to results of drug
sensitivity tests. Intermittent vaginal bleeding was also
noted with anemia (hemoglobin = 8.3 gm/dL) at 23
weeks, but improved afterwards. Corticosteroids were
given for lung maturation at 26 weeks. At 28 weeks, the
fluid leakage stopped for 5 days and amniotic fluid reap-
peared in twin B, at a depth of 2.0 cm. The family asked
to discontinue atosiban treatment due to its high cost.
One day later, uterine contractions increased, and fluid
leakage combined with vaginal bleeding relapsed. There-
fore, atosiban was restored again and the dose adjusted
to 10.5 mg/hr for 2 days, and then back to 9 mg/hr. At
30 weeks, the family asked to taper the dose of atosiban
to 6 mg/hr, once again due to its high cost. After that,
uterine contractions reinforced and large vaginal blood
clots followed. The patient complained of left lower
abdominal pain and ultrasound showed blood accu-
mulation behind twin B. An emergency Cesarean sec-
tion performed done at 30 weeks and 2 days. Twin A
had a birth weight of 1,518 g with an Apgar score of 8
and 9 at 1 and 5 minutes, respectively. Twin B weighed
830 gm only with Apgar score 1, 6 and 8 at 1, 5 and 
10 minutes respectively. The cord of twin B was very
small, and meconium stained chronically. There were
fresh and old blood clots occupying one third of the
placental base. Partial abruptio placenta was impressed
but no fetal distress noted before delivery.
The CRP level in both twins was normal when
checked at the neonatal intensive care unit but prophy-
lactic antibiotics were given. Both twins were found with
patent ductus arteriosus and recovered after two doses of
indocin (0.2 mg/kg). Initially, both twins received nasal
continuous positive airway pressure (CPAP) for venti-
lation support. Twin A recovered well and was removed
from ventilation support 6 days later and was discharged
35 days after birth with a body weight of 2,030 gm.
Twin B suffered severe intrauterine growth retarda-
tion and respiratory distress. His lung condition was
treated with high frequency oscillatory ventilation and
on the second day, inhaled nitric oxide was given. A chest
tube for left side pneumothorax was used on the third
day and extubated 9 days later. Hemivertebrae at T7-
T8 and T12 was also coincidentally noted. Brain sonog-
raphy showed intraventricular hemorrhage grade II
initially on the left side, and then persistent bilateral
grade I periventricular echogenicities noted. Persistent
CPAP dependence was noted and he started coughing
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111 days after birth. Sputum virus isolation demon-
strated parainfluenza type 3 infection. He had progres-
sive dependence on oxygen and we used high-setting
nasal intermittent positive pressure ventilation. His res-
piratory distress deteriorated thereafter and he died
120 days after birth.
Discussion
First-trimester bleeding is frequent in over 30% of ART
pregnancies, and ultimately approximately half of them
miscarry [11]. It is unknown whether first-trimester
bleeding, if it does not end in a spontaneous abortion,
negatively influences further pregnancy outcomes in ART.
First-trimester bleeding has been shown to lead to in-
creased second- and third-trimester bleeding rates,
PPROM, and extreme preterm birth [11]. In this case,
vaginal bleeding and sub-chorionic hematoma was de-
tected at 9 weeks of gestation. Polycystic ovary syndrome
in this patient may be another contributing factor of
threatened abortion [12]. Prior to formation of large sub-
chorionic hematoma, uterine contractions or so-called
“myometrial thickenings” [13] supposedly occurred ear-
lier but we have no evidence of this from her history.
Until recently, the treatment policy involved in
patients of EPPROM before 20 weeks was usually termi-
nation of the pregnancy due to risk to both the mother
and the fetus. Patients and doctors should devote more
attention to those pregnancies which are difficult to
achieve by ART. Most reported survivals for EPPROM
occur at more than 20 weeks [14–16]. Through improve-
ments in obstetrical and neonatal care, we have suc-
cessfully delayed the preterm delivery of ART twins
with EPPROM (Table) [4,5,17–22].
EPPROM in twins is more difficult to treat than
EPPROM in singletons; therefore selective fetocide of
the affected twin is a new option to accelerate the
process of leakage sealing [22]. This case was referred to
our emergency service at 22 weeks and 5 days of gesta-
tion, 32 days post-EPPROM. The EPPROM occurred in
the upper twin sac, and we successfully handled the
EPPROM of the lower twin sac [4]. After complete
counseling with the patient and her family, we decided
to attempt aggressive tocolysis to save both twins.
Unfortunately, traditional tocolytics such as ritodrine
and MgSO4 seemed unable to control her uterine activi-
ties after admission. Intolerable side effects like palpi-
tation and hot flushes occurred very shortly after the
use of ritodrine and MgSO4, even at moderate doses. For
that reason, the addition of atosiban was suggested.
Atosiban has been shown to be an effective tocolytic
agent with a low rate of side effects from 24 to 33 weeks
of gestation. It has been introduced for use in intact
membranes [23], PROM [24], or prior to cervical cer-
clage [25]. However, in a recent meta-analysis of six trials
involving 1,695 women, the atosiban failed to reduce
preterm birth, as compared with the placebo [26]. 
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Table. Assisted reproduction technology-derived twins with one extremely preterm premature rupture of membrane before
before 20 weeks of gestation
Author (year)
GA at Method of Procedures PPROM to GA at Twin A Twin B 
PPROM (wk) conception after PPROM birth (d) delivery (wk) (g) (g)
Borenstein & 15 COH – 119 32 1,100 1,500*
Shoham [17] (1990)
Wu et al [4] (1996) 19 COH – 64 28+1 1,166 1,116*
Chang et al [5] 18 AID Cerclage 72 28+2 NA* 1,232
(1996)
Abboud et al [18] 17+1 AIH Cerclage 71 27+2 NA* 1,070
(1997)
Bakos et al [19] 13+5 COH – 100 28 455* 1,270
(1998)
Jazayeri et al [20] 17 IVF Cerclage 105 32 NA* 2,070
(2002)
Hamersley et al [21] 15+2 ART Cerclage 153 37+1 NA* 2,863
(2002) 18+4 ART Cerclage 23 22 NA* NA
Keselman et al [22] 16 AIH Fetocide + Cerclage 140 36 NA* 2,500
(2008) 19 COH Fetocide + Cerclage 119 36 2,500 NA*
Present case 18+1 AIH – 85 30+2 1,518 830*
*The twin of EPPROM. AID = artificial insemination of donor; AIH = artificial insemination of husband; ART = assisted reproductive technology; COH = controlled
ovarian hyperstimulation; EPPROM = extremely preterm premature rupture of membrane; GA = gestational age; IVF = in vitro fertilization; NA = not available;
PPROM = preterm premature rupture of membrane.
In a placebo-controlled trial [27] by Romero et al involv-
ing 531 subjects, 14 atosiban-treated patients and five
placebo-treated patients were randomized at less than
24 weeks; the incidence of fetal-infant deaths was higher
for the atosiban group at less than 24 weeks. However,
in a recent prospective randomized study enrolling 40
women at less than 24 weeks gestation [28], atosiban
was shown to be effective for tocolytic treatment of pre-
mature labor, even during weeks 18 and 24 of pregnancy.
The first and only agent approved for tocolysis by
the US Food and Drug Administration was ritodrine. The
approval of that drug in 1980 initiated a period of intense
clinical exploration for other agents that might inhibit
uterine contractions [29]. However, the side effects such
as changes in maternal blood pressure, serum glucose
levels and especially the subjective symptoms of palpi-
tations lead to limited dosages of ritodrine [30]. MgSO4
is another agent commonly used for tocolysis, with recent
evidence showing elevated circulating levels of serum
ionized magnesium occurring in mothers at the time of
delivery associated with subsequent neonatal intraven-
tricular hemorrhage [31]. Conversely, a more recent
randomized controlled trial demonstrated that
MgSO4 given before very preterm birth would protect
the infant brain and no major maternal adverse effects
were observed [32]. However, monitoring the dosage,
respiratory suppression, and hot flushes compromises
the use of MgSO4.
Deliveries at 20–25 weeks of gestation are associated
with significant morbidity and mortality. If EPPROM
were to occur before 20 weeks a poorer prognosis would
be expected. In our case of twins with one experiencing
EPPROM, limited use by ritodrine and MgSO4 made
tocolysis more difficult because of side effects. Atosiban
has been shown to be beneficial in prolonging the preg-
nancy of spontaneous labor at very early gestational peri-
ods [9]. Applied even during weeks 18 and 24, atosiban
is also effective for tocolytic treatment for preterm labor
with a favorable profile of side effects [28]. Therefore, we
added atosiban combined with ritodrine and MgSO4 to
control the preterm labor. One of the major concerns of
atosiban in Taiwan is its high cost, for those pregnancies
from ART or twins, it is more economically acceptable.
One of the major neonatal outcomes of EPPROM
is pulmonary hypoplasia, which occurs in 60% of preg-
nancies at 14–19 weeks of gestation, 13% at 20–25
weeks, and 0% at 26–28 weeks in a Sweden study [33].
EPPROM in our case occurred in the upper twin sac,
where it should have been easy to stop leakage [17].
Indeed, we found amniotic fluid accumulation at 26
weeks, but leakage occurred again. Twin B had severe
intrauterine growth retardation but no evidence of infec-
tion, and was dependent on CPAP for a prolonged
period, but eventually died of pneumonia 4 months
later. His death may be attributable to pulmonary
hypoplasia from EPPROM. Thus selective fetocide of
the affective twin may be a reasonable choice under
these conditions [22].
EPPROM occurring at 14–19 weeks, 20–25 weeks,
and 26–28 weeks has perinatal survival rates of 40%,
92% and 100%, respectively [33]. In twins with one
EPPROM, the distension of the uterus may lead to a poor
prognosis. In addition to traditional tocolytic agents,
atosiban with fewer side effects may be helpful for
prolongation of those pregnancies with EPPROM.
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